Sign In
Buy PSNL
$10.78
-0.360 (-3.23%)
At Close: Jun 03, 2026
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
06:00am, Tuesday, 22'nd Apr 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
04:01pm, Wednesday, 26'th Mar 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Need
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, Lond
Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
07:40pm, Thursday, 27'th Feb 2025
Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and P
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates
06:20pm, Thursday, 27'th Feb 2025
Personalis (PSNL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.46 per share a year ago.
3 Biotech/Healthcare Names Under $10 I Am Buying Now
04:21pm, Friday, 21'st Feb 2025
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equ
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Thursday, 20'th Feb 2025
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exciting Technology At Personalis, But Profitability Eludes Them
10:50am, Friday, 14'th Feb 2025
Personalis specializes in ultrasensitive cancer detection technology, with promising products like NeXT Personal and ImmunoID NeXT, but faces profitability challenges. The company has strong financial
Personalis (PSNL) Upgraded to Buy: Here's Why
01:01pm, Monday, 20'th Jan 2025
Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
05:00am, Monday, 13'th Jan 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London's Francis Crick Institute and University College London,
Personalis price target raised to $9 from $7 at Lake Street
08:53am, Wednesday, 08'th Jan 2025
Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. W
Personalis to Participate at Upcoming Investor Conferences
04:01pm, Wednesday, 20'th Nov 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following inve
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
08:11pm, Wednesday, 06'th Nov 2024
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
06:26pm, Wednesday, 06'th Nov 2024
Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.
Personalis to Announce Third Quarter 2024 Financial Results
04:01pm, Wednesday, 23'rd Oct 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday,
